Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
The project will boost clinical development and manufacturing as Aspect expands its pipeline for metabolic and endocrine diseases, officials said.
8 Articles
8 Articles
$79 million from Ottawa supports Aspect Biosystems' $280 million development project
.bh__table, .bh__table_header, .bh__table_cell { border: 1px solid #C0C0C0; } .bh__table_cell { padding: 5px; background-color: #FFFFFF; } .bh__table_cell p { color: #2D2D2D; font-family: 'Helvetica',Arial,sans-serif !important; overflow-wrap: break-word; } .bh__table_header { padding: 5px; background-color:#F1F1F1; } .bh__table_header p { color: #2A2A2A; font-family:'Trebuchet MS','Lucida Grande',Tahoma,sans-serif !important; overflow-wrap: bre…
Feds invest $79 million in Aspect Biosystems to develop 3D-printed tissue treatment
Vancouver-based Aspect Biosystems has received significant federal support for a $280-million project to improve its 3D-printed human tissue treatment. “We are taking a major step toward building a generational company anchored in Canada and delivering life-changing therapies to patients around the world.” The company announced the project, supported by $79 million from the federal Strategic Response Fund (SRF), on Thursday morning in Vancouve…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium




